BAY 1135626 - ≥99% , CAS No.1404071-37-9

CAS: 1404071-37-9 Cat. No.: B767800 Molecular Weight: 1063.33

GRADE & PURITY ≥99%

Storage

Store at 2-8°C,Protected from light

Shipped In

Wet ice

Overview

BAY 1135626 is used to synthesize BAY 1129980 for anti-tumor research. BAY 1129980 is an ADC reagent based on Auristatin, which has anti-C4.4A (LYPD3) activity and can be used for research on non-small cell lung cancer (NSCLC).

In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

In vitro research

C4.4A (LYPD3) is a protein expressed in non-small cell lung cancer (NSCLC), with scarcely expressing in normal tissues.BAY 1135626 can be synthesized into BAY 1129980 (C4.4A-ADC), shows a strong anti-proliferative effect on C4.4A expressing cell lines.BAY 1129980 (0.001-100 nM; 72 h) inhibits the proliferation of A549 lung cancer cell lines transfected with C4.4A.BAY 1129980 (0.001-100 nM; 72 h) exhibits high and selective efficacy on hC4.4A:A549 cells in vitro. 

In vivo research

BAY 1129980 (1.9-7.5 mg/kg; i.v.; 20 d) inhibits tumor growth in vivo in mouse.BAY 1129980 with a repeated dosing (15 mg/kg; i.v.; 21 d for 1st cycle and 57 d for 2nd cycle) is well tolerated without changing the sensitivity to the treatment.

Specifications

Specifications & Purity

≥99%

Biochemical and Physiological Mechanisms

BAY 1135626 is used to synthesize BAY 1129980, and use to anti-tumor research. BAY 1129980 is a Auristatin-based anti-C4.4A (LYPD3) antibody–agent conjugate (ADC), is used to non–small cell lung cancer (NSCLC) research

Storage

Store at 2-8°C, Protected from light

Shipped In

Wet ice

This product requires cold chain shipping. Ground and other economy services are not available.

Purity

≥99%

Names and Identifiers

• Molecular Weight: 1063.33